Purdue Pharma

Judge Colleen McMahon was expected to halt work on the controversial settlement that would give immunity from opioid lawsuits to the Sackler family. Instead she allowed work on the plan to go ahead.

The DOJ is seeking to block implementation of any part of the Purdue Pharma bankruptcy deal until legal challenges are settled. The deal granted Sackler family members immunity from opioid lawsuits.

The decision by a federal bankruptcy judge grants members of the family who own Purdue Pharma, maker of OxyContin, sweeping protection from any liability for the opioid crisis.

With a federal judge poised to approve Purdue Pharma's controversial Chapter 11 plan, the company is working behind the scenes to preempt a legal challenge by the Justice Department.

Judge Robert Drain signaled he will approve the landmark bankruptcy for Purdue Pharma, the maker of OxyContin. But he called for new limits to legal protections for members of the Sackler family.

Two divisions of the DOJ argue the deal improperly shelters members of the Sackler family and their associates from liability. States are finalizing a separate deal with other opioid companies.

Massachusetts and New York are among the states agreeing to end the fight to halt a controversial Purdue Pharma bankruptcy plan. The deal shelters members of the Sackler family from opioid lawsuits.

If the bankruptcy plan is approved, Florida could get up to $280 million to $400 million over a 10-year period.

Under a bankruptcy plan filed late Monday, the OxyContin maker would pay $500 million up front, promising billions in future payments. Twenty-four states rejected the proposal.

The controversial deal hashed out between the Department of Justice and the maker of Oxycontin provides hundreds of millions of dollars of relief for communities hit hard by the opioid epidemic.